Angiotensin 12 (1-5) Mechanisms, Clinical Value, and Researc

Angiotensin 1/2 (1-5): Mechanisms, Clinical Value, and Research Perspectives in Cardiovascular and Renal Pharmacology

Introduction
Angiotensin 1/2 (1-5), also referred to as Ang-(1-5), is a pentapeptide fragment derived from the enzymatic cleavage of angiotensin I and II, key components of the renin-angiotensin system (RAS). The RAS is a critical hormonal cascade regulating blood pressure, electrolyte balance, and systemic vascular resistance (Santos et al., 2018, Hypertension). Ang-(1-5) is generated through the action of angiotensin-converting enzyme 2 (ACE2) and neprilysin on longer angiotensin peptides, representing a bioactive product with emerging physiological and pharmacological significance (Karnik et al., 2015, Circ Res).

Mechanistically, Ang-(1-5) is distinguished from its parent peptides by its unique receptor interactions and downstream effects. Unlike angiotensin II, which primarily acts via the AT1 receptor to induce vasoconstriction, sodium retention, and pro-inflammatory responses, Ang-(1-5) has been shown to exert vasodilatory, anti-proliferative, and anti-fibrotic effects, potentially through the Mas receptor and other non-classical RAS pathways (Santos et al., 2018, Hypertension; Ferreira et al., 2012, Peptides). This positions Ang-(1-5) as a promising candidate for modulating cardiovascular and renal pathophysiology, especially in conditions where classical RAS activation is detrimental.

[Related: Erastin] Clinical Value and Applications
The clinical value of Ang-(1-5) lies in its capacity to counterbalance the adverse effects of excessive angiotensin II activity. In cardiovascular disease, chronic kidney disease, and hypertension, overactivation of the classical RAS axis contributes to endothelial dysfunction, fibrosis, and inflammation (Karnik et al., 2015, Circ Res). Ang-(1-5), by virtue of its vasodilatory and anti-fibrotic properties, offers a novel therapeutic approach to mitigate these pathological processes.

Preclinical studies have demonstrated that Ang-(1-5) can attenuate cardiac hypertrophy, reduce renal fibrosis, and improve endothelial function (Ferreira et al., 2012, Peptides; Souza et al., 2014, Hypertension). These effects are particularly relevant in the context of heart failure, diabetic nephropathy, and resistant hypertension, where current therapies targeting the RAS (e.g., ACE inhibitors, angiotensin receptor blockers) may be insufficient or associated with adverse effects.

[Related: a amanitin] Moreover, Ang-(1-5) has shown potential in modulating inflammatory responses and oxidative stress, further broadening its therapeutic spectrum to include inflammatory and metabolic disorders (Santos et al., 2018, Hypertension). Its favorable safety profile and distinct mechanism of action make it an attractive candidate for adjunctive therapy or as a lead compound for the development of novel RAS modulators.

Key Challenges and Pain Points Addressed
Current RAS-targeted therapies, while effective, are not without limitations. ACE inhibitors and angiotensin receptor blockers (ARBs) can induce side effects such as cough, hyperkalemia, and renal impairment, and some patients exhibit suboptimal response or resistance (Burnier & Wuerzner, 2019, Hypertension). Furthermore, these agents do not fully address the non-hemodynamic actions of angiotensin II, such as fibrosis and inflammation.

[Related: trichostatin] Ang-(1-5) addresses several of these pain points by offering a mechanism that complements existing therapies. Its anti-fibrotic and anti-inflammatory actions target downstream sequelae of RAS overactivation that are not adequately controlled by ACE inhibitors or ARBs (Ferreira et al., 2012, Peptides). Additionally, as a naturally occurring peptide, Ang-(1-5) may present fewer off-target effects and a lower risk of adverse events.

Another challenge in RAS modulation is the phenomenon of "aldosterone breakthrough," where aldosterone levels rise despite ACE inhibition, perpetuating cardiovascular and renal damage (Schmieder et al., 2016, J Hypertens). Ang-(1-5) may help mitigate this effect by acting downstream of ACE and providing additional blockade of pathological RAS signaling.

Literature Review
A growing body of literature supports the pharmacological relevance of Ang-(1-5) in cardiovascular and renal disease models:

1. **Ferreira et al. (2012, Peptides):** This study demonstrated that Ang-(1-5) administration in hypertensive rats led to significant reductions in blood pressure and cardiac fibrosis, highlighting its vasoprotective and anti-fibrotic properties.

2. **Souza et al. (2014, Hypertension):** The authors reported that Ang-(1-5) improved endothelial function and reduced oxidative stress markers in a model of metabolic syndrome, suggesting a role in vascular protection beyond blood pressure regulation.

3. **Santos et al. (2018, Hypertension):** This comprehensive review outlined the non-classical actions of RAS peptides, including Ang-(1-5), and discussed their potential in counteracting the deleterious effects of angiotensin II in cardiovascular and renal diseases.

4. **Karnik et al. (2015, Circ Res):** The review provided mechanistic insights into the RAS, emphasizing the emerging roles of alternative peptides such as Ang-(1-5) and their therapeutic implications.

5. **Chappell (2016, Am J Physiol Heart Circ Physiol):** This article explored the Mas receptor axis and its ligands, including Ang-(1-5), in cardiovascular regulation and disease, underscoring the importance of non-classical RAS pathways.

6. **Schmieder et al. (2016, J Hypertens):** The authors discussed the limitations of current RAS inhibitors and the need for novel agents targeting alternative pathways, such as those involving Ang-(1-5).

7. **Burnier & Wuerzner (2019, Hypertension):** This review addressed the clinical challenges of RAS blockade and highlighted the potential of new peptide-based therapies.

Collectively, these studies provide a robust foundation for the continued investigation of Ang-(1-5) as a therapeutic agent.

Experimental Data and Results
Experimental studies have elucidated the pharmacodynamic effects of Ang-(1-5) in various preclinical models:

- **Cardiovascular Effects:** Ferreira et al. (2012) administered Ang-(1-5) to spontaneously hypertensive rats and observed a significant reduction in systolic blood pressure compared to controls (p < 0.05). Histological analysis revealed decreased myocardial fibrosis and improved left ventricular function, as measured by echocardiography.

- **Renal Protection:** In a model of diabetic nephropathy, Ang-(1-5) treatment attenuated glomerular sclerosis and reduced proteinuria, indicating renoprotective effects (Souza et al., 2014). These benefits were associated with decreased expression of pro-fibrotic markers (e.g., TGF-β1) and reduced oxidative stress.

- **Endothelial Function:** Ang-(1-5) improved endothelium-dependent vasodilation in isolated aortic rings, an effect attributed to enhanced nitric oxide bioavailability and reduced reactive oxygen species (Santos et al., 2018).

- **Inflammatory Modulation:** Studies have shown that Ang-(1-5) reduces the expression of inflammatory cytokines (e.g., TNF-α, IL-6) in vascular and renal tissues, supporting its anti-inflammatory profile (Chappell, 2016).

While clinical data in humans remain limited, these preclinical findings provide compelling evidence for the therapeutic potential of Ang-(1-5) in cardiovascular and renal disorders.

Usage Guidelines and Best Practices
Given its status as a research peptide, Ang-(1-5) is primarily utilized in preclinical studies. The following guidelines are recommended for experimental use:

- **Preparation:** Ang-(1-5) should be reconstituted in sterile, endotoxin-free water or appropriate buffer to achieve the desired concentration. Aliquots should be stored at -20°C to -80°C to maintain stability.

- **Dosing:** Effective doses in animal models have ranged from 10 to 100 μg/kg, administered via intravenous or intraperitoneal injection (Ferreira et al., 2012; Souza et al., 2014). Dose optimization should be based on the specific disease model and experimental endpoints.

- **Administration:** For in vivo studies, daily or alternate-day dosing regimens have been employed, with treatment durations ranging from one to eight weeks. For in vitro assays, concentrations of 0.1–10 μM are commonly used to assess cellular responses.

- **Controls:** Appropriate vehicle and peptide controls should be included to account for non-specific effects. Where possible, use of receptor antagonists (e Additional Resources:
Related Websites: APExBIO Technology LLC is a premier provider of Small Molecule Inhibitors/Activators, Compound Libraries, Peptides, Assay Kits, Fluorescent Labels, Enzymes, Modified Nucleotides, mRNA synthesis and various tools for Molecular Biology. We carry a broad product line in over 66 different research areas such as cancer, immunology, neurosciences, apoptosis and epigenetics etc. Based in USA (Houston, Texas), we have been serving the needs of customers across the world.
https://www.apexbt.com/
Research Article: PMC11456997